Smartshop & Psychedelics News
Latest news about psychedelic science, Dutch drug policy, industry developments, and the smartshop market. Updated automatically from leading sources.
Psychedelic Integration Practices Gain Focus in Healthcare
Healthcare professionals are developing standardized integration practices to help individuals process psychedelic experiences, with implications for Dutch smartshop consumers seeking therapeutic benefits.
Read full article
US Psychedelic Reform Hits Record High with 100+ Bills in 2026
March 2026 saw 11 new psychedelic bills across 7 US jurisdictions, bringing the total to over 100 bills in 35 states. This represents the most significant wave of psychedelic policy reform in American history.
Home Cultivation Key to True Psychedelic Reform, Experts Argue
Experts warn that psychedelic reform without home cultivation rights may create corporate monopolies rather than true therapeutic access.
Psychedelic Industry Shows Strong Growth in Early 2026 Report
The psychedelic industry showed strong growth in Q1 2026 with advances in drug development, regulatory frameworks, and scientific research across multiple jurisdictions.
Psychedelic Industry Shows Strong Growth in Early 2026 Review
The first quarter of 2026 brought significant advances in psychedelic drug development, regulatory frameworks, and scientific research, signaling industry maturation with implications for Dutch smartshop markets.
Psychedelic Industry Launches Quarterly Analysis Format
Psychedelic Alpha launches quarterly industry briefings to track developments in drug development, policy, and research across the growing psychedelic sector.
Psychedelic Industry Launches Quarterly Review Format in 2026
The psychedelic industry introduces quarterly briefings to track drug development, policy changes, and scientific progress, offering valuable insights for Dutch smartshop operators and consumers.
Psychedelic Industry Launches Quarterly Market Analysis Reports
Psychedelic Alpha launches quarterly industry briefings covering drug development, policy changes, and market trends. The reports provide structured analysis for stakeholders navigating the rapidly evolving psychedelic sector.
Psychedelic Industry Launches Quarterly Analysis Format in 2026
Psychedelic Alpha launches comprehensive quarterly briefings to track industry developments across drug development, policy, and research sectors in 2026.
Psychedelic Industry Shows Strong Growth in Early 2026 Report
A comprehensive quarterly report reveals strong growth in the psychedelic industry during early 2026, highlighting advances in drug development, regulatory progress, and scientific research.
Global Psychedelic Festivals: A Guide to Transformative Events
A comprehensive guide to the world's premier psychedelic festivals, exploring how these transformative gatherings combine music, art, and consciousness exploration.
Global Psychedelic Festivals: A Guide for Dutch Enthusiasts
Dutch psychedelic enthusiasts are gaining access to transformational festivals worldwide that blend music, art, and consciousness exploration. These international gatherings offer unique opportunities for personal growth while requiring careful preparation regarding local laws and cultural contexts.
Easter Psychedelic Celebrations Rise Among Dutch Consumers
Dutch consumers are increasingly turning to legal psychedelic substances available through smartshops to celebrate Easter themes of renewal and spiritual awakening. This trend reflects a broader cultural shift toward personalized spirituality backed by emerging scientific research.
Danish Researcher Explores How Psychedelics Rewire the Brain
Danish neuroscientist Gitte Moos Knudsen's research reveals how psychedelics interact with brain chemistry and neural connections, with implications for both therapy and recreational use.
Brain Science Behind Psychedelics: New Research on Serotonin Pathways
New neuroscience research reveals how psychedelics interact with serotonin pathways and brain plasticity, with important implications for therapeutic use and safe consumption practices.
Brain Expert Explains How Psychedelics Work in Neural Networks
Leading neuroscientist Dr. Gitte Moos Knudsen explains how psychedelics interact with brain serotonin systems and neural networks. Her research reveals the crucial role of set, setting, and synaptic plasticity in psychedelic experiences.
Brain Expert Explains How Psychedelics Work in Neural Networks
Leading neuroscientist Dr. Gitte Moos Knudsen explains how psychedelics interact with brain serotonin systems and why environmental setting influences neural responses.
Danish Researcher Explores How Psychedelics Reshape Brain Networks
Danish neuroscientist Gitte Moos Knudsen's research reveals how psychedelics interact with brain chemistry and the crucial role of environment in shaping neural responses.
Brain Science Reveals How Psychedelics Work in Neural Networks
New neuroscience research reveals how psychedelics interact with serotonin pathways and neural networks in the brain. Environmental factors play a crucial role in determining the nature of psychedelic experiences.
Brain Science Reveals How Psychedelics Transform Neural Networks
New neuroscience research reveals how psychedelics transform brain networks through serotonin pathways and environmental factors. This scientific understanding validates therapeutic potential while emphasizing the importance of proper set and setting.
Danish Researcher Explores How Psychedelics Rewire the Brain
Danish neuroscientist Gitte Moos Knudsen's research reveals how psychedelics interact with brain chemistry and why environmental factors significantly influence their effects.
Brain Science Reveals How Psychedelics Work at Neural Level
New neuroscience research reveals how psychedelics interact with brain serotonin systems and neural networks to produce their effects.
Neuroscientist Reveals How Psychedelics Work in the Brain
Neuroscientist Gitte Moos Knudsen's research reveals how psychedelics work through serotonin systems and synapses in the brain. Her findings provide scientific backing for safety practices in Dutch smartshops.
Robin Carhart-Harris Maps the Mind Using Psychedelic Research
British neuroscientist Robin Carhart-Harris uses advanced brain imaging to study how psychedelics affect consciousness. His research provides scientific validation for the therapeutic potential of substances legally available in Dutch smartshops.
German Psilocybin Study Shows Mixed Results for Depression
A major German clinical trial found psilocybin no more effective than placebo for treatment-resistant depression, challenging expectations about psychedelic therapy.
German Study Shows Mixed Results for Psilocybin Depression Treatment
A German clinical trial shows modest results for psilocybin in treating depression, while new research questions whether psychedelics outperform traditional antidepressants.
Otsuka Pharmaceuticals Acquires Psychedelic Firm Transcend for $1.23B
Otsuka Pharmaceuticals acquired psychedelic medicine developer Transcend Therapeutics for $1.23 billion, marking a major investment in therapeutic psychedelic research.
Otsuka Pharmaceuticals Acquires Psychedelic Firm for $1.23B
Otsuka Holdings acquires psychedelic medicine developer Transcend Therapeutics for $1.23 billion, marking a major pharmaceutical investment in methylone-based mental health treatments.
Otsuka Pharmaceuticals Acquires Psychedelic Firm for $1.23 Billion
Otsuka Pharmaceuticals has acquired psychedelic medicine developer Transcend Therapeutics for $1.23 billion, marking a major mainstream investment in the sector.
Otsuka Pharmaceuticals Acquires Psychedelic Firm for $1.23B
Otsuka Pharmaceuticals announces $1.23 billion acquisition of Transcend Therapeutics, marking a major investment in methylone-based psychedelic treatments for mental health disorders.
Otsuka Acquires Psychedelic Drug Developer Transcend for $1.23B
Japanese pharmaceutical giant Otsuka acquires methylone drug developer Transcend Therapeutics for $1.23 billion, marking a major investment in psychedelic medicine.
Otsuka Acquires Methylone Developer Transcend for $1.23B
Otsuka Pharmaceutical's $1.23 billion acquisition of methylone developer Transcend Therapeutics marks one of the largest investments in psychedelic medicine. The deal signals growing mainstream pharmaceutical interest in compounds previously associated with smartshops and underground markets.
Billionaire Takeover of Lykos Reshapes MDMA Therapy Future
Billionaire investors are reshaping MDMA therapy research through a major corporate takeover of Lykos Therapeutics. This transformation could significantly impact European psychedelic access and regulatory approaches.
10 Mind-Bending Destinations for Psychedelic Experiences Worldwide
From spiral museums to Northern Lights, discover the world's most extraordinary destinations for psychedelic experiences. Safety and legal considerations included for responsible exploration.
US Congress Proposes VA Office for Psychedelic Therapy Research
US Congress introduces fourth psychedelics bill this term, proposing a VA office dedicated to researching novel therapeutics including psychedelic treatments for veterans.
US Veterans May Get Dedicated Psychedelic Treatment Office
New US legislation proposes creating a Veterans Affairs Office of Novel Therapeutics to explore psychedelic treatments for military mental health conditions.
US Veterans May Get Access to Psychedelic Therapy Under New Bill
New US legislation proposes creating a VA Office of Novel Therapeutics to explore psychedelic treatments for veterans, marking the fourth psychedelics-related bill this congressional term.
US Veterans May Get Access to Psychedelic Therapy Under New Bill
New US legislation proposes establishing a VA Office of Novel Therapeutics to explore psychedelic treatments for veteran mental health conditions.
US Veterans Bill Could Reshape Global Psychedelic Therapy Access
New US legislation would create a VA office for psychedelic therapies, potentially influencing global policy and accelerating mainstream acceptance of alternative mental health treatments.
Psychiatrist Warns Approval Won't Fix Psychedelic Care Scaling
Cleveland Clinic psychiatrist Dr. Brian Barnett warns that regulatory approval alone won't solve the complex challenges of scaling psychedelic medicine to widespread clinical use.
Psychiatrist Warns Approval Won't Fix Psychedelic Care Scaling Issues
Cleveland Clinic psychiatrist Dr. Brian Barnett discusses the challenges facing psychedelic medicine beyond regulatory approval, emphasizing infrastructure and scaling issues.
Psychiatrist Warns Approval Won't Fix Psychedelic Care Challenges
Cleveland Clinic psychiatrist Dr. Brian Barnett warns that FDA approval alone won't solve the systemic healthcare challenges facing psychedelic medicine implementation.
Psychiatrist Warns Approval Won't Fix Psychedelic Care Challenges
Cleveland Clinic psychiatrist Dr. Brian Barnett warns that regulatory approval alone won't solve the fundamental challenges of scaling psychedelic medicine within existing healthcare systems.
Scaling Psychedelic Care: Lessons from Ketamine Implementation
Dr. Brian Barnett's research reveals that scaling psychedelic therapy requires far more than regulatory approval, emphasizing the need for specialized training and comprehensive care frameworks.
FDA Psychedelic Approvals Progress Despite Political Turbulence
FDA psychedelic approvals advance despite political challenges, with ibogaine receiving exceptional regulatory treatment while advocacy groups undergo internal restructuring.
US Psychedelic Approvals Progress Despite Political Uncertainty
Despite political uncertainty, multiple FDA approvals for psychedelic therapies remain on track while advocacy groups adapt to changing election year dynamics.
FDA Psychedelic Approvals Progress Despite Political Turbulence
FDA psychedelic approvals appear on track despite political chaos and advocacy divisions in Washington, with industry insiders expressing quiet confidence about regulatory progress.
FDA Psychedelic Approvals Near as 'Ibogaine Exceptionalism' Emerges
FDA psychedelic therapy approvals appear imminent despite political uncertainty, with ibogaine receiving preferential regulatory treatment. These developments could significantly impact Dutch smartshop policies and European regulatory approaches.
Leading Psychiatrist Champions Data-Driven Psychedelic Research
Dr. Charles Nemeroff leads groundbreaking psychedelic research at Dell Medical School, emphasizing data-driven approaches to substances like ibogaine for treating depression and addiction.
Dr. Charles Nemeroff Leads Groundbreaking Ibogaine Research
Dr. Charles Nemeroff leads innovative ibogaine research at Dell Medical School, strengthening the scientific foundation for psychedelic therapy. His data-driven approach offers valuable insights for Dutch smartshop consumers interested in evidence-based psychedelic use.
US Government Backs 5-MeO-DMT Research in Psychedelic Breakthrough
The US government is accelerating 5-MeO-DMT clinical trials as federal support for psychedelic research reaches unprecedented levels, potentially influencing global drug policy.
US Government Boosts 5-MeO-DMT Research with Federal Backing
The US government is accelerating 5-MeO-DMT clinical trials with federal support, marking a significant shift in psychedelic research policy. This development has important implications for Dutch smartshops and the broader therapeutic psychedelic industry.
US Government Boosts Psychedelic Research with 5-MeO-DMT Trials
The US government accelerates support for psychedelic research with new 5-MeO-DMT clinical trials, marking a significant policy shift toward therapeutic applications.
US Federal Support Accelerates 5-MeO-DMT Clinical Research
The FDA is accelerating clinical trials for 5-MeO-DMT therapy, marking a significant shift in US federal policy toward psychedelic research. This development could influence global markets and regulatory approaches to consciousness-altering substances.
Mixed Results in Psychedelic Drug Trials Show Industry Challenges
Recent clinical trials show mixed results for psychedelic therapeutics, with Helus Pharma reporting unclear outcomes for their DMT analog while AtaiBeckley advances multiple programs.
Psychedelic Research Updates: Mixed Results and New Trial Designs
Recent clinical trials show mixed results for DMT anxiety treatment while MDMA and psilocybin programs advance toward potential therapeutic applications.
Mixed Results for Psychedelic Trials as Industry Advances
Recent clinical trials show mixed results for psychedelic treatments, while Dutch smartshops continue providing legal access to natural alternatives.
AtaiBeckley Seeks Partnership for 5-MeO-DMT Depression Treatment
AtaiBeckley is in advanced partnership talks for its intranasal 5-MeO-DMT depression treatment, with major pharma companies showing increased interest following recent industry consolidation.
AtaiBeckley Pursues Partnership for 5-MeO-DMT Depression Treatment
AtaiBeckley is in advanced partnership talks for its intranasal 5-MeO-DMT depression treatment, with major pharmaceutical companies showing increased interest following recent industry acquisitions.
Psilocybin Research Explores Creative Enhancement Potential
University of Texas researchers are conducting the first modern study examining psilocybin's potential to enhance creativity and problem-solving abilities.
Psilocybin Research Explores Creativity Enhancement Potential
University of Texas researchers are conducting the first modern study on psilocybin's potential to enhance creativity and problem-solving abilities.
Psilocybin Study Validates Creativity Benefits Dutch Users Know
University of Texas research validates what Dutch smartshop users have long known: psilocybin significantly enhances creativity and problem-solving abilities. This scientific backing strengthens the Netherlands' unique position in the global psychedelic landscape.
Major Study Finds Microdosing Effects Last Only One Day
New research involving 1,435 participants reveals that microdosing benefits may only last for the day of consumption, similar to coffee's effects.
Major Microdosing Study Reveals Effects Last Only Hours, Not Days
New research involving 1,435 participants reveals that microdosing benefits last only hours rather than days, challenging assumptions about sustained effects.
Major Microdosing Study Finds Benefits Limited to Dosing Day
A large-scale study of 1,435 microdosers reveals that benefits from psychedelic microdosing may last only on the day of consumption, challenging expectations of multi-day effects.
Quarter of Americans Back Medical Psilocybin Use, RAND Study Finds
New RAND Corporation research shows 25% of Americans support legal psilocybin use, with therapeutic applications driving public acceptance over recreational interests.
RAND Study: Therapeutic Benefits Drive US Psychedelic Support
New RAND Corporation research shows nearly 25% of US adults support psilocybin legalization, driven primarily by therapeutic rather than recreational benefits.
Oregon Psilocybin Centers Face Closures Amid Regulatory Challenges
Oregon's regulated psilocybin therapy program faces challenges as service centers close due to high licensing fees and regulatory burdens, offering lessons for international psychedelic policy development.
Washington State Debates Two Competing Psychedelic Reform Models
Washington state lawmakers debate two competing approaches to psychedelic regulation, reflecting national tensions between medical oversight and decriminalization models.
FDA Approves Psilocybin PTSD Trial as Therapy Gains Momentum
The FDA has approved Compass Pathways' psilocybin compound for PTSD clinical trials, marking a significant step toward legitimizing psychedelic therapy in mainstream medicine.